StockUS listing USVBIZFPINKHealthcareValue Trap

Viva Biotech Holdings(VBIZF) Stock Analysis | Healthcare

USD --+0.00%
Reward45Moderate
Risk56Medium-High
75%Data
Revenue down 15% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 724.45M
Reward Ratingⓘ45 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ56 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on VBIZF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Viva Biotech Holdings?

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.

AI Brief Pro

The brief on Viva Biotech Holdings

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Viva Biotech Holdings?

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 724.45M, and a P/E ratio of 34.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (45)
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap724.45M
Beta1.717
Insider Activity
12M windowNo data
No insider activity data available for this ticker.